Interim Report January - March 2003

BIOINVENT INTERIM REPORT 1 JANUARY - 31 MARCH 2003 q Acquisition of drug project in the cancer field from research group at the Karolinska Institute in Stockholm, Sweden. q So far six target structures have been accepted into the collaboration with Oxford GlycoSciences. q Patent applications submitted within the framework of the collaboration with GlaxoSmithKline and within the Protein array field. q q Net revenue for January - March 2003: SEK 16.8 million (18.0). Loss after net financial items for January - March 2003: SEK -20.8 million (-11.7). q q Cash flow from current operations and investment activity for January - March 2003: SEK -17.8 million (24.4). Liquid funds at year end: SEK 325.7 million (363.1). q Contact: Any questions regarding this report will be answered by: Svein Mathisen, President and CEO, +46 (0)46 286 85 67, mobile +46 (0)708 97 82 12 or Jonas Källmén, CFO, +46 (0)46 286 38 12, mobile +46 (0)708 77 48 07. The report is also available at BioInvent International AB (publ.) Co. reg. no. 556537-7263 ------------------------------------------------------------ This information was brought to you by Waymaker The following files are available for download: The full report The full report

About Us

BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer. The company has unique expertise in antibody drug development from initial concept to late clinical phase. The antibody library n-CoDeR and the screening tool F.I.R.S.T. are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at